The fallout from the U.S. crackdown on Huawei intensified this week, as trade negotiations between Washington and Beijing reportedly hit a roadblock.Asia Marketsread more
The issue of corporate debt has surfaced as companies continue to use the low rates the Fed has provided to lever up their balance sheets.The Fedread more
The U.S. government on Monday temporarily eased some trade restrictions imposed recently on China's Huawei, a move that sought to minimize disruption for the telecom company's...Technologyread more
Google has decided to stop licensing its Android operating system to Huawei, in order to comply with a U.S. trade blacklist.Technologyread more
Most U.S. hedge funds aren't expecting another big stock market sell-off as more firms curb bets on volatility, according to Nomura.Marketsread more
Mall owners are increasingly building out food halls with local chef-driven eateries, sushi bars and premium coffee shops.Retailread more
While Trump's lawyers had argued that the committee's subpoena did not have a legitimate legislative purpose — and was therefore invalid — Mehta took a broader view.Politicsread more
See which stocks are posting big moves after the bell on Monday, May 20.Market Insiderread more
Silicon Valley argues that Wall Street focuses too much on near-term profits — but investors have embraced money-losing biotech IPOs.Marketsread more
Iran has quadrupled its output of nuclear material amid rising tension with the U.S. and dangerous escalations in the Middle East.Energyread more
The announcement comes amid a wave of store closures across the country this year.Retailread more
PayPal: "Here's the thing that you need to know: this stock has now dropped 5 straight points. Another 2 points and it's really going to be oversold and then, and only then, would I pull the trigger."
Senseonics: "If you're going to do glucose monitoring, if you want to be conservative, you buy Abbott. If you want to be a little more aggressive, you buy Dexcom. Those are the only two that I really care about. "
Idexx Laboratories: "Idexx Labs is the kind of stock that does come down here and that is exactly when you buy it. Another [$]5 [and] I think it's perfect."
Sonos: "No, no, no, no. That's not the kind of stock you buy into weakness. That is not the kind of stock that is going to bounce right back. That is the kind of stock that has very inconsistent numbers. Let's stay away. Don't buy."
Denbury Resources: "I think you've had a really good run in that one. It's not a really high-quality company. That group is struggling. I'd say ring the register."
Apptio: "To me, this is a worrisome situation because I've got cloud stocks that are going down and I want to buy the cloud kings when they go down. Salesforce is going down– I mean, congratulations, Marc and Lynne Benioff. Buying Time Magazine, I think, is good and it's totally separate from Salesforce. But Salesforce is going down. I'd rather see you in some high-quality stock like that. "
Invitae: "I have looked at this company when I did the Biotech Bible for TheStreet.com and I felt that it was way too speculative. But you know what? This thing has just roared. But it's not mine. It's too speculative for me. As long as you understand that it is a spec, then you're OK."
Wayfair: "You know, this is one that I'm going to tell you I'm not the call on. I really liked it. I thought it would go higher. I never thought it would get to this level. At these prices, I think it's too high, but why listen to me? I actually was saying that for the last 20 points."
JD.com: "That is way too speculative and I am not a believer in Chinese stocks. There isn't a single one that I'm recommending. There. That's it."
Disclosure: Cramer's charitable trust owns shares of PayPal, Abbott Laboratories, Salesforce.com and Microsoft.